tiprankstipranks
Trending News
More News >

Shandong Xinhua Pharmaceutical Secures Drug Registration for Isavuconazonium Sulfate

Story Highlights
  • Shandong Xinhua Pharmaceutical focuses on prescription drugs in the pharmaceutical industry.
  • The company received approval to market Isavuconazonium Sulfate, boosting its market position.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Shandong Xinhua Pharmaceutical Secures Drug Registration for Isavuconazonium Sulfate

Don’t Miss TipRanks’ Half-Year Sale

Shandong Xinhua Pharmaceutical Company Limited Class H ( (HK:0719) ) has issued an update.

Shandong Xinhua Pharmaceutical Company Limited announced that it has received the Drug Registration Certificate for Isavuconazonium Sulfate for Injection from the National Medical Products Administration. This approval marks a significant milestone for the company, allowing it to produce and market this prescription drug, potentially enhancing its market position and offering new opportunities for growth within the pharmaceutical sector.

More about Shandong Xinhua Pharmaceutical Company Limited Class H

Shandong Xinhua Pharmaceutical Company Limited is a pharmaceutical company based in China, primarily engaged in the production and sale of prescription drugs. The company focuses on developing chemical drugs and has a market presence in the pharmaceutical industry.

Average Trading Volume: 4,260,784

Technical Sentiment Signal: Buy

Current Market Cap: HK$9.58B

See more insights into 0719 stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1